Karyopharm Therapeutics (KPTI) Other Non-Current Liabilities (2014 - 2026)

Karyopharm Therapeutics (KPTI) has 8 years of Other Non-Current Liabilities data on file, last reported at $11.1 million in Q4 2025.

• Quarterly Other Non-Current Liabilities rose 356.58% year-over-year to $11.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.1 million (up 356.58% YoY) and the FY2025 annual result came in at $11.1 million, up 356.58% from the prior year.
• Other Non-Current Liabilities declined to $11.1 million in Q4 2025, from $73.5 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $133.0 million in Q4 2021 to a low of $978000.0 in Q4 2023.
• A 5-year average of $66.0 million and a median of $73.5 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Other Non-Current Liabilities tumbled 99.18% — and 2024, when it surged 12110.05%.
• Tracing KPTI's Other Non-Current Liabilities over 5 years: stood at $133.0 million in 2021, then changed by 0.0% to $133.0 million in 2022, then plunged by 99.26% to $978000.0 in 2023, then soared by 148.47% to $2.4 million in 2024, then jumped by 356.58% to $11.1 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $11.1 million (Q4 2025), $73.5 million (Q3 2025), and $73.5 million (Q2 2025), per Business Quant data.